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Abstract
The field of transcranial electrical stimulation (tES) has experienced significant growth in the past 
15 years. One of the tES techniques leading this increased interest is transcranial direct current 
stimulation (tDCS). Significant research efforts have been devoted to determining the clinical 
potential of tDCS in humans. Despite the promising results obtained with tDCS in basic and 
clinical neuroscience, further progress has been impeded by a lack of clarity on international 
regulatory pathways. We therefore convened a group of research and clinician experts on tDCS to 
review the research and clinical use of tDCS. In this report, we review the regulatory status of 
tDCS, and we summarize the results according to research, off-label and compassionate use of 
tDCS in the following countries: Australia, Brazil, France, Germany, India, Iran, Italy, Portugal, 
South Korea, Taiwan and United States.
Research use, off label treatment and compassionate use of tDCS are employed in most of the 
countries reviewed in this study.
It is critical that a global or local effort is organized to pursue definite evidence to either approve 
and regulate or restrict the use of tDCS in clinical practice on the basis of adequate randomized 
controlled treatment trials.
1. Introduction
The field of transcranial electrical stimulation (tES) has experienced significant growth as 
evidenced by the number of peer-reviewed publications on non-invasive Brain Stimulation 
(NIBS) in the past 15 years, as well as by the exponential increase in the number of 
laboratories involved with such research. One of the NIBS techniques leading this increased 
interest is transcranial direct current stimulation (tDCS). The exponential growth of tDCS 
reflects the ease of use of this method in addition to its so far favorable profile combined 
with its ability to produce significant effects on human neural plasticity (1).
Significant research efforts have been devoted to determining the clinical potential of tDCS 
in humans. The data from numerous studies conducted by international teams have 
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repeatedly shown that tDCS can provide clinical benefits for several conditions such as 
major depression (2, 3), stroke (4-9), aphasia (10-12), chronic pain (13-15), Alzheimer 
(16-19), Parkinson (20) and schizophrenia (21), with no major side effects. Further, the 
research utility of tDCS has proved valuable in elucidating brain circuit function by 
providing a tool capable of safely modulating neurophysiology and behavior in humans 
(22-26). Despite these advancements in diverse applications of tDCS in basic and clinical 
neuroscience, however, further progress is needed in some countries such as, for instance, 
South Korea, where lack of specific regulations for tDCS research has been slowing down a 
research development. Also the lack of a plan for regulatory approvals for trials testing 
clinical approaches may also decrease future interest. Thus, there has been an increased need 
for regulations governing the use of tDCS and this has been called for by practitioners, 
patients and regulatory agencies.
As clinical and neuroscience research on tDCS is an international effort, and collective 
safety and efficacy experience influences ongoing work, it is critical to organize and 
compare regulatory consideration on federal and global level. We therefore convened a 
group of research and clinician experts on tDCS to review the research and clinical use of 
tDCS. In this report we summarize the evidence and review the regulatory status of tDCS in 
Australia, Brazil, France, Germany, India, Iran, Italy, Portugal, South Korea, Taiwan and 
United States. These countries were chosen as some of the productive researchers in tDCS 
are from these countries. We also include at the end of this article an opinion summary from 
the group regarding its clinical and research use. The group selected to be part of this article 
is composed from leaders in tDCS research in each respective country, as evidenced by the 
scientific production of the members. In addition, all the members are affiliated with leading 
academic, industrial, and/or regulatory agencies.
There are well-established laws for the regulation of medical device distribution and use in 
most developed countries, such that it is incorrect to focus on the “need” for regulation but 
rather clarity and consistency in how standing regulations are applied to tDCS. Ambiguity 
among clinicians and researchers can lead to lack of access to equipment and unfortunate 
substitutions such as a less suitable devices and accessories being used. This document 
therefore places the use in the tDCS in the context of existing international regulations.
2. Overview of Regulatory Process
With regard to this topic, it is important to clarify the definition of a “Medical Device”. The 
regulatory bodies and agencies of different countries have adopted various positions and 
standards in defining a Medical Device. According to the United Stated Food and Drug 
Administration (FDA) a medical device is defined as:
"An instrument, apparatus, implement, machine, contrivance, implant, in vitro 
reagent, or other similar or related article, including a component part, or 
accessory” that is recognized for the use in diagnosis, prevention and treatment in 
humans without using chemical pathways.
The FDA has established three different classifications for Medical Devices designated as 
Class I, Class II, and Class III with different standards and controls ensuring safety and 
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efficacy depending on the risk of the device. For example, dental floss and band aids are 
Class I Medical Devices, non-invasive blood pressure monitors, and OTC TENS devices for 
treatment of pain or for aesthetic purposes represent examples of Class II Medical Devices, 
and heart replacement valves or deep-brain stimulating electrodes are exemplars of Class III 
Medical Devices. It is important to note that nearly all non-invasive or cutaneously 
administered electrical stimulation devices have been deemed Class II medical devices by 
the FDA stemming from more than 40 years of accumulated data on their safe use. Based on 
the FDA definition of a medical device, and recognizing the spectrum of devices regulated, 
it is thus logical to include tDCS devices - whether indicated for medical treatments, 
diagnostic purposes, wellness aids, entertainment devices or for any other purpose - as a 
Medical Device according to the FDA.
3. Safety and adverse effects
With the typical current levels and experimental protocols (27), the side effects of tDCS are 
mild, benign, and short-lived. In a recent systematic review, Brunoni et al. (28) assembled 
data from tDCS studies performed up to 2010. Out of 172 articles, 56% mentioned adverse 
effects and 63% reported at least one adverse effect. Importantly, when they were 
systematically assessed, the rates of common adverse effects did not differ between the 
active arms of the studies and the sham arms. These included itching (39.3% vs. 32.9%, 
respectively), tingling (22.2% vs. 18.3%), headache (14.8% vs. 16.2%), burning sensation 
(8.7% vs. 10%) and discomfort (10.4% vs. 13.4%). However, most studies reviewed did not 
systematically assess adverse effects. Therefore, we suggest that publication of tDCS trials 
should require systematic assessment and report of the intensity and frequency of adverse 
effects, even if they are mild or if none are observed.
While it is commonly ignored, tDCS-induced erythema (skin reddening) is an adverse effect 
significantly more common in active vs. sham groups (29-31). The erythema presumably 
occurs due to an increase in blood flow of dermal vessels accompanying the current 
application. Although this effect is generally benign, it might compromise study blinding in 
randomized, sham-controlled trials (29) and therefore should be minimized by following the 
standard procedures regarding tDCS applications. Recently it has also been suggested that 
the topical pretreatment with Ketoprofen could reduce the tDCS-induced erythema (32). On 
rare occasions, tDCS application has led to skin burns (33). However this appears to occur 
only when standard procedures regarding tDCS application (such as correct preparation of 
the skin, humidification of sponges with saline, limit of voltage/current above a maximum 
impedance etc.) are not followed (22, 34). Therefore, the safety of tDCS is limited to use 
with appropriate tDCS equipment, accessories, and protocols.
According to the FDA, and similarly to other international regulatory agencies, serious 
adverse events are those in which the outcome is (i) death, (ii) life-threatening, (iii) 
hospitalization, (iv) disability/permanent damage, (v) congenital anomaly/birth defect, (vi) 
required intervention to prevent permanent impairment or damage (for implantable devices), 
(vii) and other serious events - e.g., refractory seizures, cardiorespiratory arrest, anaphylactic 
reaction etc. No serious adverse events attributable to tDCS have been reported in more than 
10,000 subjects investigated in the contemporary tDCS literature (1998-2014). Specifically, 
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there have been no reports of cardiorespiratory arrest, seizures, or brain damage. In addition, 
specific tests have been conducted for serum enolase, a protein associated with neuronal 
death, with no significant effect (35) and for evidence of structural brain damage (36). 
Studies have examined and found no significant abnormal changes in 
electroencephalographic activity (37) or in heart rate variability (38-40). The threshold for 
adverse effects was suggested in a safety study in rats (41), where the charge density 
necessary to induce brain damage in rats was found to be at least 100 times higher than the 
charge density used in tDCS trials. Because skin discomfort and pain are induced with 
currents even 2-3 times higher than that used in most tDCS experiments, it is highly unlikely 
that the safety threshold would be ever reached in human tDCS studies.
Interestingly, there is a description of one case report in 1964 of “respiratory and motor 
paralysis with cramping of the hands, (…) nausea, [and without] loss of consciousness” 
during electrical stimulation (34).The authors later acknowledged that a current 10 times 
higher than the intended amperage was accidentally delivered to this subject (34) . Although 
the conditions of the stimulation in this event, or even the nature of the adverse behavioral 
response are unclear, this report provides an important reminder of the risk when electrical 
stimulation is applied outside the range of well-studied parameters. The risk of permanent 
injury is posed by “Do It Yourself tDCS” (DIY-tDCS) (42) that fosters home and un-
supervised tDCS applications, outside the controlled settings of laboratories and clinical 
centers. Importantly, risk designation by the IRB or FDA is specific to both the device used 
and clinical protocol-thus changing any aspect of the device, electrodes, protocol (e.g. 
increasing dose), or include/exclusion requires re-examination if risk-level. This last point is 
critical in regards to the so-called “DIY-tDCS” movement or ad-hoc commercial products – 
these cannot claim the benefit of the robust safety record of clinical tDCS precisely because 
they deviate in these aspects.
3.1. Recommendations based on Evidence to Date
Here we summarize information regarding the safety of tDCS for the benefit of research 
ethics committees and Institutional Review Boards, as well as in clinical practice. The 
application of tDCS has presented minimal risk in numerous studies when it has been 
applied in research or clinical studies within standard parameters. Minimal risk means there 
have been no serious adverse events, that common adverse effects such as reddening of the 
skin are mild and short-lived, and that reasonable efforts at assessment have determined 
there is no evidence of brain damage. Standard parameters to date mean that (1) the current 
is less than 2.5 mA, (2) it is applied through electrodes that are known to minimize skin 
burns at the specific current level, (3) the current application duration is less than 20-60 min 
per session, and (4) that sessions are not more frequent than twice per day. This does not 
imply that exceeding these stimulation parameters will result in substantial risk, but that 
experience with these stimulation parameters is limited, and thus definite statements are not 
possible to date. tDCS can be described as a noninvasive procedure in the standard medical 
usage of this term meaning that it does not involve penetrating the skin or a body cavity. 
Nonetheless, the application of electrical current to the brain has been shown to induce 
functional changes (neural plasticity) that, although being the targeted physiological effect, 
can represent also a potential risk for the patient or participant. Although tDCS has been 
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shown to be safe and effective in many experiments, the stimulation parameters, if chosen 
incorrectly, might lead to maladaptive plasticity rather than adaptive or positive effects on 
neural plasticity. In fact, this is particularly important when combining with a behavioral 
therapy. It is important that the given behavioral therapy is associated with adaptive effects.
The safety of tDCS has been demonstrated primarily for short-term use. The effects of long-
term use are largely unknown, and there are not enough follow-up studies to understand the 
effects of continued tDCS over the long-term (43). There are few studies assessing chronic 
use of tDCS. The safety and efficacy of daily to twice-daily, domiciliary, 30-min, 1- to 3-
mA tDCS sessions across nearly 3 years was reported in a patient with schizophrenia (44) . 
The longest acute treatment trials to date have delivered about 6 weeks of tDCS, with up to 
30 sessions of tDCS (40, 45). These studies show no increased incidences of adverse events; 
though data is still limited.
Finally, tDCS is a complex and as yet poorly understood method of manipulating the 
physical properties of neural tissue. Ethical use requires that the researcher or clinician have 
current scientific knowledge of the rapidly developing literature, such that research or 
clinical practice is guided by new evidence on safety and efficacy as it becomes available.
4. Efficacy
A fundamental effect of tDCS is that it is able to modulate cortical excitability (46-50), 
therefore tDCS has been examined as a potential therapeutic intervention in multiple clinical 
disorders, including depression, chronic pain, stroke, Alzheimer and Parkinson’s disease 
(17, 18, 45, 51-59).
One of the main clinical applications being tested with tDCS is stroke. For instance, daily 
sessions of tDCS improve upper limb function in stroke patients (60), as well as increase 
scores on activities of daily living (ADLs). These findings have been confirmed by,meta-
analysis where various montages of tDCS -- with or without adjunct physical therapy -- 
improve motor function in mild to moderate stroke patients (60).
Besides motor function in stroke, language recovery has also been explored with tDCS. 
Anodal tDCS over perilesional areas improves language function, but the effect was found 
to persist over time only when tDCS was coupled with language training (61, 62). More 
research is required to evaluate the effectiveness of tDCS for practical language 
rehabilitation (anodal/cathodal/dual), primarily through examining the stability of the 
improvement over clinically significant intervals of time (63). For example, using cathodal 
stimulation over the injured cortex, Monti, et al (61) showed that, although the tDCS 
treatment in aphasia induces a gain in speech performance of approximately 25%, this effect 
was transient.
There has been considerable interest in treating depression with tDCS applied 
asymmetrically to the frontal lobes (typically with anodal electrode over left dorsolateral 
prefrontal cortex and cathode over right supraorbital cortex). The most recent meta-analysis, 
incorporating all RCTs to date, found that active tDCS was more effective than a sham 
stimulation comparator (64). However, given the limited number of RCTs available (N=7), 
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evidence for the antidepressant efficacy of tDCS cannot be considered conclusive, and 
further trials are required. Earlier meta-analyses reported mixed findings, likely because of 
heterogeneity in the evidence base (65, 66). An important consideration may be concurrent 
antidepressant drug treatment. When tDCS was used as monotherapy, a 63% response rate 
was observed, with more than doubling of the remission over sham control (65). In other 
reviews of tDCS and depression, the odds ratio for (OR) favorable symptom response was 
1.63; (95% CI = 1.26-2.12] and the OR for remission was 2.50 (95% CI = 1.26-2.49) (64). 
When an acute course of tDCS was followed by weekly to fortnightly maintenance tDCS 
sessions, the cumulative probability to avoid relapse was of 83.7% at 3 months, and 51.1% 
at 6 months (67). When Major Depressive Disorder (MDD) and Bipolar Depressive 
Disorder (BDD) were examined separately, five sessions of anodal stimulation induces a 
beneficial effect that persists at one week and one month in both groups (3).
There has been also an effort to use tDCS for enhancing cognitive function in patients with 
Alzheimer, suggesting that tDCS can positively improve memory performance (16, 17, 19); 
and that the after effects of repetitive sessions of tDCS seem to outlast for at least 4 weeks 
(17).
In patients with schizophrenia that were refractory to medication, cathodal tDCS over the 
left temporoparietal junction (TPJ) coupled with anodal tDCS over the left dorsolateral 
prefrontal cortex (DLPFC) reduces auditory verbal hallucinations on 31%, lasting for up to 3 
months. Also, general severity of illness improves on the Positive and Negative Syndrome 
Scale (ES =0.98, 95% CI=0.22–1.73) (21).
In studies of tDCS effects on pain sensitivity in healthy subjects, anodal stimulation leads to 
an increment in pain threshold and better tolerance compared to sham stimulation (68). The 
cathodal stimulation reduces the sensitivity to A†-fiber-mediated cold sensation and C-fiber-
mediated warm sensation compared with baseline, whereas Aß-fiber-mediated 
somatosensory inputs were less affected (69). In patients undergoing the total knee 
arthroplasty, tDCS reduces opioid consumption and pain level (70). For treating chronic 
pain regardless of etiology, the ES of tDCS has been estimated between −2.29 (95% CI= 
−3.5 to −1.08) (71) and −0.86 (95% C.I., −1.54, −0.19) (72). Although a pre-specified 
subgroup analysis in meta-analysis with distinct types of chronic pain indicated that tDCS 
was superior than sham (ES −0.59, 95% CI −1.10 to −0.08) (29) a further meta-analysis 
failed to detect a superiority of tDCS over sham in reducing pain (73), possibly due to 
heterogeneity. The analgesic effect of tDCS combined with a technique of visual illusion 
induces better effect regarding all pain subtypes, while the tDCS alone improves only in 
continuous and paroxysmal pain (74).Also, tDCS combined with visual illusion improves 
neuropathic pain in spinal cord injury with 50% mean decrease of symptoms (58). In 
episodic migraine without aura anodal preventive treatment reduces migraine attack 
frequency, migraine days, attack duration and acute medication intake. This benefit persists 
on average 4.8 weeks after the end of treatment (75). In chronic migraine the anodal effect 
applied on primary motor cortex induces a delayed response (56). Recent evidence also 
points to the potential of tDCS for the treatment of phantom limb pain (76, 77).
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Although the findings on treating pain with tDCS have thus been varied, the effects with 
chronic pain are promising, and may justify the use of tDCS to treat pain in selected patient 
populations. For the most part, the studies of anodal stimulation have demonstrated at least a 
moderate size effect. Two excitability-enhancing (anodal) tDCS montages have resulted in 
analgesic effects, one montage with the anode over the primary motor cortex with mean ES 
of 9.59% (13, 15, 78, 79) and another montage with anode over the DLPFC with mean ES of 
15.79% (80). Typically, the analgesic effects have been shown to be cumulative, with the 
majority of clinical trials providing stimulation on 5 consecutive days (with some extending 
over 10 days). Problems in this research have been (1) the heterogeneity of the studies that 
make specific comparisons difficult, (2) the lack of systematic intention to treat designs, and 
(3) the high dropout rates. Finally, new placebo-controlled studies of tDCS for the treatment 
of pain are required that include a systematic follow-up according to the recommendations 
of the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (81).
tDCS has also been used to decrease craving associated with food, smoking, cocaine and 
alcohol. A recent meta-analysis examined the use of frontal lobe tDCS (and rTMS) to reduce 
craving, considering both craving in substance dependence and craving for high palatable 
food (82). Both rTMS and tDCS over the DLPFC revealed a SE of 0.48 (95%CI: 
0.316-0.636), with no significant difference between these treatments. In the application to 
manage tinnitus, anodal tDCS reduces the intensity of this symptoms with a SE of 0.77 
(95% CI= 0.23-1.31) (83). Finally, anodal tDCS over the pre-motor areas also improves 
sleep and fatigue symptoms in patients with post-polio syndrome (84).
5. Current Status on the use of TDCS
Table 1 summarizes the current regulatory status of tDCS in Australia, Brazil, France, 
Germany, India, Iran, Italy, Portugal, South Korea, Taiwan and United States. These 
countries were chosen given some of the leading researchers of tDCS are from these 
countries.
5.1 Australia experience
In Australia, medicines and therapeutic medical devices are regulated by the Australian 
Therapeutic Goods Administration (TGA), which has a Register of approved medicines and 
devices. Currently, no tDCS machines are registered with the TGA. Thus, for each clinical 
trial in which tDCS is used, apart from obtaining approval from the institution’s Research 
Ethics Committee for the trial protocol, a Clinical Trial Notification form needs to be lodged 
with the TGA, noting the trial protocol ID and providing specifications of the machine to be 
used. For use outside a clinical trial (eg basic physiological research), the research protocol 
should be approved by the institution’s Research Ethics Committee but does not need to be 
lodged with the TGA. Further, some professional societies may provide their own guidelines 
about the use of tDCS. For example, the Royal Australian and New Zealand College of 
Psychiatrists states “Transcranial Direct Current Stimulation (tDCS), another innovative 
brain stimulation treatment that does not involve seizure induction, has shown promise in 
recent trials for the treatment of depression. Until further data is available, it should only be 
given within approved research protocols.” (Position Statement #79 on Repetitive 
Transcranial Magnetic Stimulation, revised Oct 2013). There have been anecdotal reports of 
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practitioners providing tDCS as a treatment to patients for depression outside formal 
research protocols and without TGA notification, i.e. practice that is outside regulatory 
approvals.
In Australia, tDCS research commenced in the mid 2000’s with randomized controlled trials 
of tDCS in depression. Research interests have rapidly expanded and currently include the 
application of tDCS to the treatment of depression, schizophrenia, mild cognitive 
impairment and pain management. In addition, research groups have focused on cognitive 
effects of tDCS, and the use of neuroimaging and computer modelling to understand the 
effects of tDCS.
5.2 Brazil experience
Since 2005, Brazil has been involved with pioneering clinical trials testing tDCS for some 
clinical conditions such as stroke (85), pain (78), cognition(47), Parkinson (86), tinnitus (87) 
and depression (88).
The use of tDCS in clinical research is regulated by the local ethics committee (Comitê de 
Ética em Pesquisa, CEP), which follows the statement of ethical principles from the World 
Medical Association-Declaration of Helsinki (89). In most cases, the CEP has enough 
autonomy to approve a clinical research proposal using tDCS. In some circumstances, 
particularly in centers where tDCS use is less common, the CEP consults the National Ethics 
Committee (Comitê Nacional de Pesquisa, CONEP) in order to approve a clinical tDCS 
research.
The Health Related Products in Brazil needs to be approved by the Brazilian Health 
Surveillance Agency (ANVISA), which is a governmental regulatory agency characterized by 
its administrative independence and financial autonomy. To date, the only device registered 
by ANVISA (the health agency that regulates approval of medical devices and drugs in 
Brazil) to specific use as tDCS is the “DC – STIMULADOR” from the company 
“NEUROCONN GMBH”. The approval from ANVISA would be similar for instance to the 
CE mark for devices used in Europe and also shares similarities with FDA approval for 
medical devices.
Besides ANVISA clearance, professional societies, in some cases, also make 
recommendations for use of medical devices and drugs. To date, the only professional 
society that has issued recommendations is the occupational therapist and physical therapy. 
In their resolution it says that tDCS can be used “for treatment of individuals, when 
combined with physical therapy, with the aim of controlling pain, improving sensorimotor 
function and cognition” (COFFITO – Resolution, 434, Sep 27, 2013). Although their 
resolution gives ON-label approval for a broadly use of tDCS; additional details for each 
indication taking into consideration the levels of scientific evidence for specifics situations 
are necessary and thus need to be considered carefully by the clinician employing this 
technique.
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Finally, it should be underscored that the “compassionate use” of tDCS may be allowed in 
Brazil, in circumstances in which the patient is not eligible for a clinical trial and there are 
no satisfactory, alternative clinical therapies.
5.3 France experience
For now, French health authorities have not approved the use of tDCS for any condition 
clinically. The use of tDCS for clinical and research purposes in healthy participants and 
patients should be restricted to studies, predominantly clinical trials. The use of tDCS for 
clinical purpose should be restricted to hospital and labeled research units and should be 
delivered in medical environment allowing an optimal management of adverse events. 
Serious adverse events occurring during protocols must be declared to ethical and health 
authorities within 24 hours to warrant the safety survey of the device. tDCS is usually 
carried out by trained technicians, nurses, psychologists or assistants under the supervision 
of a medically responsible licensed physician.
All protocols involving Humans receiving non-invasive brain stimulation have to obtain an 
approval by a regional ethical committee (i.e., CPP: Comité de protection de personnes) and 
by the national French agency for medicines and health products safety (ANSM). The 
benefit/risk ratio and the safety of the device must be clearly exposed for each novel 
protocol or indication. An independent scientific evaluation, a subscription to a specific 
insurance for the study and a justification that the budget to complete the study was already 
obtained are usually recommended before the statement of the ethical committee. The device 
must have a CE mark for medical use.
“off-labele” (off-label) applications such as patients suffering from resistant disabling 
symptoms can be envisaged with the approval of an ethical committee. In this case, the 
benefit/risk ratio must be clearly in favor of therapeutic benefits for the patient. In all cases, 
patients must be clearly informed and must give their written informed consent. The cost is 
not paid for by national or private health insurances.
tDCS is used in France by several teams for clinical and research purposes. Clinical uses are 
mainly for neuropsychiatric conditions (e.g., chronic pain, stroke, depression, schizophrenia, 
addiction). Groups of professionals aim to establish guidelines; for instance, French users of 
tDCS for psychiatric purposes have developed a national association organizing annual 
training courses and scientific meetings to warrant optimal and safe use of tDCS in 
accordance with recent international literature (STEP section from French Association for 
biological psychiatry and neuropsychopharmacology).
5.4 Germany experience
The regulatory situation for application of tDCS in Germany is complex. With regard to 
application of tDCS in research, it has to be discerned between clinical trials, and non-
clinical studies. Clinical trials are defined by the aim to explore clinical, physiological, and 
side effects of a drug or device, in the context of establishing or improving a clinical 
treatment tool, which is usually not certified for clinical use (90). These studies, which are in 
most cases initiated by the producer of the device, have to be approved not only by the local 
ethics committee, but also by the respective federal organization, the BfARM (Federal 
Fregni et al. Page 10













Institute for pharmaceutical and medical products). For all other studies, which do not fulfill 
these criteria, which is the case for most tDCS protocols, approval by the local ethics 
committee is sufficient. In the past, however, there has been often confusion about this 
regulation, because the wording of the respective laws, and regulations, suffers from some 
fuzziness. With regard to approval by the ethics committee, no formal criteria, such as about 
“minimal risk” do exist, which gives the committees some freedom of decision to evaluate 
risk-benefit relations. No major difficulties have been experienced however to receive ethics 
approval to perform respective studies in the past, although, especially when the committee 
has not been confronted with this specific research field before, it might be necessary to 
deliver very detailed information about protocol, and safety aspects.
For clinical application of tDCS beyond studies, off-label treatment (in terms of 
compassionate use) is principally possible, but will in most cases not be compensated for by 
the health insurances. In these cases, informed consent of the patient, detailed 
documentation, and clarification that the individual treatment, and not scientific interest, is 
the main cause for the therapeutic decision, are critical.
5.5 India experience
Research studies on tDCS from India have been on increase in the recent past (91). Most of 
these research reports are based on IRB approved protocols that have followed stringent 
guidelines with respect to the safety of tDCS administration that match contemporary 
international standards (92). Significant bulk of these publications has illustrated the clinical 
utility of tDCS in schizophrenia as a monotherapy, add-on treatment in acute phase of 
psychosis resulting in quicker amelioration of symptoms (91) insight facilitation into illness 
(92). In addition, studies from India have reported certain important leads towards the 
understanding of possible neurobiological basis for beneficial effects of tDCS in 
schizophrenia (93). However, all these studies are of open-label nature; currently, controlled 
studies with stringent research design are in progress to ascertain the potential leads obtained 
in earlier reports.
With regards to the regulation of tDCS usage in India, it is noteworthy that until recent past, 
the application of medical devices in India has remained largely unregulated. In 2013, the 
Government of India has introduced the Drugs and Cosmetics (Amendment) Bill to establish 
several quality control measures with regards to the regulation of medical devices 
application; the implementation of this bill into an act is still in progress. Meanwhile, the 
contemporary use of tDCS in India is primarily regulated by stringent review of study 
protocols by the IRB of respective institutes. Similar review of protocols by IRB’s is 
expected for targeted tDCS application using arrays of small electrodes termed as HD-tDCS. 
In India, currently, systematic applications of tDCS are predominantly restricted to research 
studies to understand the neurobiological mechanisms and to facilitate its implementation 
for treating various neuropsychiatric disorders like schizophrenia.
5.6 Iran experience
Iran should be considered as a good sample among developing countries with no or limited 
exposure to tDCS. tDCS as a low-cost and easy to use technology provides both researchers 
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and clinicians in Iran and other developing countries with new opportunities for clinical, 
cognitive, brain mapping, and computational modeling studies and finally clinical services. 
There are limited but growing numbers of publications from Iranian institutes using tDCS 
for stroke, pain, and drug addiction patients since 2011. In 2014, one private company and 
one university affiliated research group have received funds for “Research and 
Development” studies to produce different range of tDCS devices “to be used in research 
settings but not for clinical use” with options for alternating and random noise currents and 
high definition stimulations. But, they are obligated to receive governmental approval to be 
able to sell their devices in the official market to the Labs with “tDCS labels”. In Iran, tDCS 
devices are under the control of medical technologies office of Food and Drug Organization 
at Ministry of Health and to our best knowledge, no Iranian company has received any 
approval from this office yet to sell tDCS devices produced in Iran (June 2014), but, an 
international company is registered there to sell tDCS devices in Iran.
Ethical committees in Iranian universities are the main approval reference for tDCS studies 
as “non or minimally invasive interventions”. All clinical trials using tDCS must be 
registered in Iranian Registry of Clinical Trails (IRCT). First approvals from ethical 
committees for tDCS studies were time consuming regarding the lack of knowledge for 
tDCS among committee members, but now it could be done in less than 3 months in most of 
the universities. The major challenge for getting an ethical approval for tDCS studies in Iran 
is for children subjects (under age 18).
Basically, there is no official approval for “on-label” use of tDCS as a clinical service in 
Iran. But, there are growing numbers of clinical centers using tDCS as an “off-label” 
intervention for a wide range of disorders including tinnitus, stroke (mainly aphasia and 
dysphagia), depression, auditory hallucination, drug addiction, and etc. based on their 
professional and ethical regulations as a member of Islamic Republic of Iran Medical 
Council (IRIMC). Insurance companies do not cover any costs related to tDCS 
interventions. There was an expert panel in Islamic Republic of Iran Psychology and 
Counseling Council (IRIPC), as the main regulatory body for the psychological 
interventions in the country on May 2014, discussing applying technologies such as 
neurofeedback, biofeedback, tDCS and TMS, by registered psychologists. This expert panel 
concluded that psychologists should abandon any electric or magnetic stimulatory 
intervention without presence and supervision of an in-charge medical doctor. Based on 
Iranian experiences with recent exposure to tDCS as a new medical technology with 
potential benefits for clinical populations, we would recommend other developing countries 
with no or limited experience with tDCS to put wide range of educational programs at their 
first priority. Policy makers, granting agencies, regulating bodies, researchers, clinicians and 
even public audiences should be targeted with educational programs regarding potentials, 
threads, challenges, hopes, abuse potentials and regulations for clinical use of tDCS.
5.7 Italy experience
tDCS, first applied in Italy several years ago for the non-invasive modulation of cortical 
excitability (94) in more recent years, it has increasingly gained attention as one of the most 
innovative approaches under investigation as therapeutic tool for neurological diseases. In 
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particular, the primary area of application is the rehabilitation of cognitive impairments in 
patients with Alzheimer’s disease and the treatment of motor and language disorders in 
stroke patients (18, 61, 62, 95). Noteworthy, the IV Italian Report on stroke published in 
2014, which focuses to innovations in the field of stroke prevention and rehabilitation, has a 
section dedicated to tDCS (96). More recently, it has been proposed for the treatment of 
neuropathic pain and hemicrania and, in neuropsychiatry, for depression and psychosis (3, 
97). In stroke rehabilitation, tDCS is largely used as add-on intervention to standard 
physical/cognitive therapies, generally administered in the chronic stage of illness (98). The 
treatment protocols generally include randomized designs with at least ten tDCS sessions on 
consecutive weekdays (20 min, 2mA). Although being considered as minimal risk, 
therapeutic applications of tDCS follow the same recommendations for the use and safety of 
transcranial magnetic stimulation.
To date many Italian research institutions have set up ad-hoc neuromodulation laboratories, 
accessible to both in- and out-patients, dedicated to basic and clinical research with tDCS. 
Clinical trials are typically conducted by a multidisciplinary team of professionals with 
expertise in various areas, such as neuropsychology, neurophysiology, and neurology and 
they are carried out by trained technicians, usually a psychologist or a medical assistant 
under the supervision of a neurologist. A licensed physician serves as medically responsible 
clinician, closely supervising the tDCS application and medical conditions of the patients. In 
some Italian hospital and private medical centers, tDCS is offered as off-label treatment and 
is authorized as standard treatment, but it needs to undergo specific ethic committee 
approval. Medical doctors can also prescribe tDCS free of charge for outpatients under the 
heading of electrotherapy but the structure where tDCS sessions will take place should be 
authorized for that prescription.
5.8 Portugal experience
In Portugal, as with many other countries it is necessary to make the distinction in research 
studies between clinical trials and non-clinical trials.
Non-clinical trials only require approval from the local ethics committee(23, 24) following 
the general guidelines established in the declaration of Helsinki (89), even if they pose more 
than minimal risk.
Clinical trials require also initial approval from the local ethics committee, and then a formal 
approval from the National Authority for Drugs and Health Products (infarmed - Autoridade 
Nacional do Medicamento e Produtos de Saúde, I.P.). There is also a mandatory online 
registration in the national database of clinical trials (PNEC – Portal Nacional de Ensaios 
Clínicos) that will be also available through the European Clinical Trials Portal - EU 
Clinical Trials Register. There are also additional steps if the medical device is not CE 
marked.
To the best of our knowledge there are currently no infarmed approved tDCS devices. In 
order to approve one, the manufacturer or its representative in the European Union (EU) 
needs to apply for a validation of the device, providing all the required information. After 
that, the medical device needs to be classified based on the potential risk for humans. Device 
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and accessories are assessed independently based on a set of criteria (e.g. invasiveness), and 
the device receives an overall classification based on the element, which can potentially 
pose more risk.
Compassionate treatments are possible after approval from the local ethics committee. Off 
label treatments are not regulated by the infarmed. Lastly, the use of medical devices will 
also be based on the internal regulations of professional societies based on the empirical 
evidence, which will determine what constitutes the “clinical procedure”, the required 
training to perform it, and who is certified to administer it.
5.9 South Korea experience
A medical device that potentially poses safety hazards to the intended user should first be 
approved by the Korean Ministry of Food and Drug Safety (MFDS) before it can be legally 
marketed and sold. According to personal communications with the MFDS, the MFDS 
regards tDCS as having a risk profile equivalent to Class II, which is an even higher risk 
category than transcranial magnetic stimulation (Class III). Currently, there is no 
government approved tDCS device for brain stimulation on the market in Korea. Therefore, 
the application for product approval of tDCS should be undertaken for any clinical use. In 
order to secure product approval, technical documents, along with clinical study reports, 
have to be submitted and reviewed by the MFDS. Regarding the evidence of clinical study 
reports, preexisting clinical data from studies conducted outside Korea can be submitted. 
However, if the MFDS judges that the data are not sufficient to judge the clinical efficacy of 
the medical device, a formal clinical trial for product approval should be conducted in 
Korea.
A scientific clinical trial can be conducted regardless of product approval considerations. 
MFDS and the local institutional review board (IRB) should approve the study protocol. A 
protocol submitted to the MFDS should not only contain the detailed clinical study protocol, 
but also detailed technical information about the device; this requirement may be onerous 
and require significant administrative work by the clinical researcher for submission. This 
process should be repeated for every research study using tDCS; tDCS devices explicitly 
used for clinical trial should be destroyed afterwards. The approval criteria for study 
protocols using tDCS are inconsistent among local IRBs: Some IRBs initially offer 
conditional approval requiring further approval by MFDS; however, other IRBs may offer a 
full approval of the study protocol without any review by MFDS probably due to lack of 
knowledge regarding MFDS’s strict regulation. This is an important concern given that 
some protocols may not follow then all regulatory needs in Korea according to the Korean 
Medical Appliances Act.
A search using the keywords “tDCS” or “transcranial direct current stimulation,” along with 
“Korea,” on the PubMed search engine between 2008 and 2014 resulted in a total of 29 
articles. Approval of study protocol by a local IRB was described in 26 articles; there were 
no available descriptions of IRB approval in the other three articles – which may indicate 
either lack of reporting or research without necessary IRB approval.
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The current regulatory situation of tDCS in Taiwan is quite similar to that of Germany. As 
of now the tDCS (including HD-tDCS) device is not considered as a medical device in 
Taiwan, and thus non-clinical research only requires the approval of the local ethics 
committee, without the need to obtain approval from the Food and Drug Administration 
(FDA) of Taiwan. Clinicians can also apply for minimal risk or regular IRB applications to 
the ethics committee in hospitals. However, since tDCS is still a novel research tool in 
Taiwan, the IRB process can be different from time to time, depending on the reviewers’ 
degree of familiarity towards brain stimulation. In the absence of a set of clearly defined 
clinical protocols for tDCS, in our experience it is useful to provide details of tDCS effect 
and possible risk or side effects based on reports from the literature or international safety 
guidelines (99) to the IRB committee. Note that as of now researchers in Taiwan may 
sometimes encounter difficulties when trying to import tDCS devices due to different 
interpretations among officials on whether tDCS should go through the clearance process of 
a medical device. In our view, it is important for researchers and clinicians to engage in 
crosstalk with regulation agencies to facilitate the establishment of a more comprehensive 
regulation and protocols for the safe use of tDCS in research contexts.
5.11 US experience
In the US, medical devices, such as tDCS are, regulated by the FDA. As noted above, the 
FDA definition for a medical device would include any brain stimulation device, including 
tDCS, and thus tDCS in the US can be regulated as a medical device regardless of 
indications for use. Clinical trials using tDCS are regulated under the “Investigational 
Device Exception” (IDE) that allows for human research pending controls, documentation, 
and monitoring by both the manufacturer and investigator. Every clinical trial with tDCS 
requires an IDE approval by the FDA except for defined exceptions. These exceptions 
include those clinical trials which are determined by the (local) institutional IRB to be “non-
significant-risk” (NSR) - such trials are provided a de-facto “expedited IDE” by the FDA 
and are subject to reduced by specific regulatory burden by the manufacturer and 
investigator.
To our knowledge, in the US, IRBs ubiquitously (at a minimum overwhelmingly) designate 
tDCS trials NSR (see adverse event discussion above), thus not requiring a formal IDE 
application to the FDA. At investigator/IRB discretion, the FDA may be directly asked to 
provide a risk-designation for a trial. To our knowledge, in response to such requests that are 
trial specific, the FDA generally considers tDCS trials as NSR (100-102). Even if a trial is 
considered significant-risk, it may be ethically approved by the IRB/FDA (or funding 
agency such as NIH) if the benefits offset risk and/or appropriate measure are taken to 
control risk.
Based on FDA statutes and other device precedents, we are aware of no legal basis for 
tDCS, for any application and any use, to be excluded from medical device regulations the 
US. The production and distribution of medical devices in the US is subject to strict 
regulations including FDA Quality Systems. We recommended that the devices and 
protocols not reproducing clinical tDCS in regards to device/electrode design and protocols 
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(including strict dose control, include/exclusion, professional monitoring), not be conflated 
with tDCS in regards to safety or efficacy.
The granting of an (expedited) IDE is not indicative of clearance by the FDA to market 
devices for uses other than “investigational” ones or plans to approve tDCS for the treatment 
of a disease – but only the sanctioning of a clinical trial. The US FDA clears devices only in 
response to specific manufacturers request to review products, not spontaneously or in 
general based on a body of medical research. In the absence of such a manufacturer 
application, tDCS has not been cleared by the US FDA for the treatment of any medical 
indication. At the time of the writing of this article, the only companies having an IDE for 
tDCS devices from the FDA were Soterix Medical (tDCS and HD-tDCS) and, NeuroConn. 
However, many IRB-sanctioned studies have been able to gain NSR approval using off-label 
devices or devices available from commercial sources not having an IDE.
In the US, physicians may prescribe treatment to patients that are “off-label” subject to 
professional and ethical guidance. Off-label conventionally implies using a therapy 
considered safe and without changing dose, applying it for an indication or intended use 
other than that which has been cleared by the FDA. In this sense, the adaptation of 
Iontophoresis devices - especially with outputs exceeding conventional tDCS protocols and 
with accessories not designed for the scalp - should be approached with caution since the 
dose and technology is different than devices designed for tDCS. Notably common 
Iontophoresis devices are not designed to be applied across the head as its electrodes and 
methods to control current may not be ideal for such purpose. We recommend that tDCS 
devices are strictly output-limited consistent with conventional tDCS protocols.
The FDA has developed various guidance documents for expedited regulation of non-
invasive electrical stimulation devices (with indications ranging from aesthetic to clinical) 
with either prescription of over-the-counter access; though pending these provide a basis for 
considering “Limited Output” tDCS. tDCS should not be confused with FDA designated 
Cranial Electrotherapy Stimulation (CES) that is not a comparable dose (not Direct Current)
(103).
6. Conclusion
tDCS is a relatively safe technique, associated with mild side effects such as itching, 
tingling, headache, burn sensation, and discomfort (22, 34). tDCS is easy to administer and 
its use within standard parameters (as defined above) has been associated with minimal risk 
of serious adverse effects.
There is now promising clinical evidence about the effects of tDCS in several clinical 
conditions such as depression, stroke, chronic pain, tinnitus, schizophrenia, amongst others 
(15, 18, 21, 76, 78, 88), especially when applied with other therapies (104, 105) . There is 
also available data for phase II/III clinical trials combining tDCS with other intervention for 
major depression (104). However, large trials are still needed to confirm the effects of tDCS 
when testing in a more heterogeneous samples, taking into account more its clinical and 
functional outcomes.
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According to our review, tDCS can potentially be used as an off-label treatment in Iran, 
Germany, US, Italy, Brazil and France. The regulations for off-label treatment vary 
according to the country’s internal policies and in most of the cases there is not a clear 
policy in place for the off-label use of tDCS. In some cases off-label use requires IRB//
Ethical Committee and/or medical executive approval. The device needs also to be approved 
for clinical use. Presently, only Iran, US, Europe and Brazil have such approved devices. 
But, for instance, in some cases, such as US, the only approved devices are Iontophoresis, 
which may not be the optimal ones, namely because of the type of electrodes and the 
parameters that typically exceed the standard parameters defined above. Off label treatment 
should then be conducted with caution, as presently there is insufficient data about the long-
term use of such treatments.
Another option is to use it as “compassionate treatment”. According to the FDA, the use of a 
medical device in patients which do not meet the inclusion criteria for clinical research, is 
possible if the physician believes that such use could benefit the treatment of that disease or 
condition. In that sense, based on the severity of the disease or condition, and in the absence 
of other treatment alternatives, tDCS can been used as a compassionate treatment option. 
This seems to be the case in most countries, with the exception of South Korea, where such 
option seems not to be possible.
In terms of research, in most countries, only IRB/Ethical Committee approval is required, 
and usually the studies using tDCS are considered to be of minimum risk. France and South 
Korea require an additional approval form their National Health Agency. But it seems that 
most IRB approve the protocol based on the promising data already available, without major 
concerns or obstacles.
Nonetheless clear guidelines about the standard tDCS application protocols, which include 
parameters such as duration, intensity, standardized adverse effects assessment and 
reporting, amongst others, are still needed. Then IRBs/Ethics Committees and national 
agencies can have at their disposal guidelines that can be useful for a harmonization of the 
regulatory requirements that seems to be impairing the development of tDCS in some 
countries. In the event that the results from brain stimulation studies is confirmed on larger 
samples of subjects and the optimal parameters to use during stimulation (i.e. intensity, 
duration, areas to stimulate) will be determined, tDCS may be a good tool for the treatment 
of different neurological and neuropsychiatric disorders as additional treatment option. 
Indeed this technique requires portable devices and may represent an additional economical 
and practical treatment for the rehabilitation of patients at home. Moreover, because tDCS 
electrodes are simply secured to the scalp and leave the patient free to move, it can be easily 
delivered during rehabilitation (online stimulation). Our international review with some of 
the most productive and leading researchers in this area has shown that tDCS has been 
considered safe for research protocols at a global level and given its initial effect and safety 
profile, there has been increasing pressure for the clinical use of this device as seen by its 
off-label and compassionate use in many of the countries surveyed in this review. It is 
therefore imperative that a global or local effort is organized to pursue definite evidence to 
either approve or abandon the use of tDCS in the clinical practice on the basis of adequate 
randomized controlled treatment trials and also as to regulate its safe clinical use. Though 
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tDCS seems to be an easy tool to use, it is also easy to misuse it, in turn with lack of efficacy 
or even inducing worse, adverse effects.
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